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OBJECTIVE—The generation of mature cell types during pan-
creatic development depends on the expression of many regula-
tory and signaling proteins. In this study, we tested the
hypothesis that the transcriptional regulator Islet-1 (Isl-1),
whose expression is ﬁrst detected in the mesenchyme and
epithelium of the developing pancreas and is later restricted to
mature islet cells, is involved in the terminal differentiation of
islet cells and maintenance of islet mass.
RESEARCH DESIGN AND METHODS—To investigate the
role of Isl-1 in the pancreatic epithelium during the secondary
transition, Isl-1 was conditionally and speciﬁcally deleted from
embryonic day 13.5 onward using Cre/LoxP technology.
RESULTS—Isl-1–deﬁcient endocrine precursors failed to ma-
ture into functional islet cells. The postnatal expansion of
endocrine cell mass was impaired, and consequently Isl-1 deﬁ-
cient mice were diabetic. In addition, MafA, a potent regulator of
the Insulin gene and -cell function, was identiﬁed as a direct
transcriptional target of Isl-1.
CONCLUSIONS—These results demonstrate the requirement
for Isl-1 in the maturation, proliferation, and survival of the
second wave of hormone-producing islet cells. Diabetes 58:
2059–2069, 2009
T
he vertebrate pancreas is crucial in maintaining
nutritional homeostasis. The pancreas is com-
posed of an exocrine compartment, consisting of
acinar and ductal cells that secrete and transport
digestive enzymes into the duodenum, and an endocrine
compartment, consisting of the islets of Langerhans that
produce hormones for regulating glucose metabolism.
Each islet comprises ﬁve cell types: , , , ε , and PP cells
expressing the hormones glucagon, insulin, somatostain,
ghrelin, and pancreatic polypeptide, respectively (1–4).
Development of the endocrine pancreas occurs in two
phases during mouse embryogenesis (5). The primary
transition at embryonic day (E)9.5 is marked by the
epithelial outgrowth of foregut endoderm into the sur-
rounding splanchnic mesoderm forming the dorsal and
ventral pancreatic buds. During this time, clusters of
ﬁrst-wave glucagon
 and/or insulin
 cells appear by bud-
ding from the pancreatic epithelium. However, the cells
lack key proteins associated with functional - and -cells
and are not believed to populate the adult islet (3,5). A
distinct second wave of hormone
 cells delaminate from
the pancreatic epithelium around E13.5 to E15.5; these
cells proliferate and mature into the islet cells (6,7). Final
organization of the islet structure is completed soon after
birth (6).
Loss- and gain-of-function studies in mice have revealed
the importance of transcription factors in endocrine pan-
creas development. Although some transcription factors
are required in multiple stages of endocrine cell develop-
ment, others are required at speciﬁc stages of the forma-
tion of islet cell types (8). For example, neurogenin 3
(Ngn3) is a central regulator of endocrine cell speciﬁca-
tion whose expression is essential for all endocrine cell
development (9,10). However, many transcription factors
are essential for early embryonic survival; therefore,
tissue-speciﬁc gene deletion strategies in mice are needed
to uncover their function in late development. For in-
stance, Foxa2 null mice die shortly after gastrulation
because of abnormal development of node and notochord
(11,12), and speciﬁc roles in endocrine cell differentiation
and islet cell function were only revealed using tissue-
speciﬁc gene ablation approaches (13–16). Similarly, the
embryonic and postnatal roles of the panendocrine tran-
scription factor Pax6 were identiﬁed only when both Pax6
null and conditional mice were investigated (17,18). In
contrast to Pax6, MafB, though expressed in developing -
and -cells, is required for cell maturation (e.g., hormone
gene expression) but not cell speciﬁcation (19,20). On the
other hand, MafA is uniquely expressed in insulin
 cells of
the secondary transition in rodents; however, no obvious
developmental defects were observed in MafA null mice,
likely because of compensation by MafB (21–23).
Like Pax6, the panendocrine cell transcription factor,
Islet-1 (Isl-1) is expressed during development in the
central nervous system, cardiac mesoderm, and pancreas
and is critical for the differentiation of these organs
(24–27). Unfortunately, Isl-1 null embryos die by E10.5
because of defective heart formation; thus, it remains
unclear as to whether Isl-1 is involved in the establishment
of pancreatic endocrine cells during the secondary transi-
tion (24–26). However, Isl-1 null mice exhibit impaired
genesis of the embryonic dorsal pancreatic bud and lack
glucagon
, insulin
, or somatostatin
 cells in vivo or after
culturing mutant pancreatic explants in vitro (24).
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have derived mice speciﬁcally lacking this factor in the
pancreatic epithelium to examine its function in islet cell
development during the secondary transition. We demon-
strate that loss of Isl-1 from the pancreatic epithelium at
E13.5 leads to a severe reduction in hormone-expressing
cells and the eventual loss of islet mass. We show that Isl-1
controls the proliferation and survival of endocrine cells in
the postnatal pancreas. Furthermore, reduced insulin gene
transcription and -cell function appear to at least par-
tially result from a speciﬁc defect in MafA gene transcrip-
tion, which we identify as a direct Isl-1 target. These
results demonstrate the importance of Isl-1 in the produc-
tion of endocrine hormones and the maintenance of
endocrine cell mass during and after the secondary
transition.
RESEARCH DESIGN AND METHODS
Animals and breeding strategy. The derivation of the Isl-1
LoxP and Pdx1-
Cre transgenic line has been reported previously (28,29). All mice were kept
on a mixed outbred CD1 background. Pdx1-Cre;Isl-1
L/ and Isl-1
L/L mice
were mated to generate Pdx1-Cre;Isl-1
L/L mutant mice. Littermate Isl-1
L/L,
Isl-1
L/, and Pdx1-Cre;Isl-1
L/ were indistinguishable from mixed CD1 Isl-
1
/ controls in our assays. Animal experiments were approved by the
Children’s Hospital of Philadelphia’s institutional animal care and use
committee.
Glucose tolerance tests and analytical procedures. Overnight fasted
animals were injected intraperitoneally with 2 g glucose (Sigma) per kilogram
of body weight. Blood glucose values were monitored at 0, 15, 30, 60, 90, and
120 min after injection using an automatic glucometer (One Touch Ultra;
LifeScan). To prepare plasma, blood was collected in heparinized tubes (BD
Microtainer), spun, and stored at 80°C until assayed. Plasma insulin levels
were measured using a Luminex kit (Linco). Total pancreatic insulin and
glucagon content were assessed by radioimmune assay of acid-ethanol
extracts at the University of Pennsylvania Diabetes Center.
Immunoﬂuorescence/immunohistochemistry. Tissues were ﬁxed in 4%
paraformaldehyde (PFA) overnight at 4°C and then embedded in either
parafﬁn or optimal cutting temperature freezing medium. Slides (8–10 m
sections) were subjected to microwave antigen retrieval in 10 mmol/l citric
acid buffer (pH6.0) and blocked with protein blocking reagent (Immunotech).
Slides were incubated with primary antibodies overnight at 4°C, and appro-
priate secondary antibodies were added for2ha troom temperature. The
following primary antibodies were used: Glucagon (1:3,000; Linco), insulin
(1:1,000; Linco), somatostatin (1:3,000; Santa Cruz), pancreatic polypeptide
(1:50; Zymed), ghrelin (1:200; Santa Cruz), Isl-1 (1:50; Developmental Studies
Hybridoma Bank 39.4D5 and 40.2D6), Pax6 (1:500; Covance), MafA (1:1,000;
Bethyl Laboratories), and Pdx1 (1:200; Santa Cruz). Ngn3 (1:500; Developmen-
tal Studies Hybridoma Bank), Cy2, Cy3, and Cy5 conjugated secondary
antibodies (1:600; Jackson ImmunoResearch). The Developmental Studies
Hybridoma Bank Isl-1 monoclonal antibodies were developed under the
auspices of the National Institute of Child Health and Human Development
and are maintained by The University of Iowa, Department of Biology (Iowa
City, IA).
RNA isolation, cDNA synthesis, and real-time PCR reactions. Total RNA
from homogenized pancreata was extracted using the RNA Easy Kit (Qiagen).
RNA was reverse transcribed using 1 g Oligo(dT) primer, Superscript II
Reverse Transcriptase, and accompanying reagents (Invitrogen). Real-time
PCR reactions were set up using the Brilliant SYBR Green PCR Master Mix
(Stratagene). All reactions were performed in triplicate with reference dye
normalization, and median cycling threshold values were used for analysis.
Primer sequences are available upon request.
Measurement of -cell mass. Pancreata were removed, weighed, ﬁxed in 4%
PFA overnight at 4°C, and embedded in parafﬁn. Sections (8–10 m) with
maximum footprint were used for insulin staining. Images were taken under
4 magniﬁcation, and pancreatic tissue positive for insulin staining was
measured by using IP Lab software. The -cell mass was obtained by
measuring the fraction of insulin-positive staining to total cross-sectional area
and multiplying by the pancreatic weight. One section was used per pancreas
with at least four control and mutant mice analyzed at each time point.
Pax6
 cell and hormone cell quantitation. Immunostaining of Pax6 was
used to detect late endocrine progenitors (hormone
 or hormone
 (30);
individual hormone immunostains were used to mark mature endocrine cell
subtypes. Pancreatic cross-sectional area was measured using IP Lab soft-
ware. At E15.5 (n  6), two adjacent sections with the largest pancreatic
footprint were selected. Pax6
 cells were counted, and the results were
normalized to cross-sectional area. To measure the differentiation of endo-
crine cell subtypes, the number of hormone-expressing cells was expressed
relative to the number of Pax6
 cells. The same technique was used to
measure endocrine cell subtypes at E18.5 (n  3), except that the average was
taken of 	10 sections taken at seven-section intervals through the block. At
P4 (n  4), Pax6
 cells were counted in four sections and normalized to
pancreas cross-sectional area.
Transferase-mediated dUTP nick-end labeling and bromodeoxyuridine
assays. The rate of apoptosis was evaluated by transferase-mediated dUTP
nick-end labeling (TUNEL) staining using the ApopTag Peroxidase In Situ
Apoptosis Detection Kit (Chemicon). Sections were processed for the TUNEL
assay, and adjacent sections were stained with an anti-Pax6 antibody. The
percentage of TUNEL
 endocrine cells was generated by dividing the number
of TUNEL
 cells to the number of Pax6
 cells. Insulin staining was performed
on the same section as TUNEL assay to locate islets. For bromodeoxyuridine
(BrdU) assays, pregnant animals (E18.5) and pups were injected with 10 l/g
of BrdU Labeling Reagent (Zymed) and killed 6 h later. BrdU staining was
performed with the BrdU Staining Kit (Invitrogen). Sections were labeled with
BrdU antibody, and adjacent sections were stained with an anti-Pax6 anti-
body. The percentage of BrdU
 endocrine cells was generated by dividing the
number of BrdU
 cells into the number Pax6
 cells. Insulin staining was
performed on the same section as BrdU staining to locate islets. At least 2,000
Pax6
 cells were counted for each animal for both TUNEL and BrdU assays,
and the number of Pax6
 cells was used for normalization.
Electrophoretic mobility shift assays. pCS2 rat Isl-1-Myc plasmid (gift
from Dr. Pfaff) was used as a template for in vitro translation of Isl-1-Myc
using Quick Coupled Transcription/Translation System rabbit reticulocyte
lysate reagents (Promega). DNA binding reactions (20 l ﬁnal volume)
included 1 l of in vitro translated protein or 10 g of Ins-1 -cell line nuclear
extract (24–26) and 400 fmol of
32P-end labeled oligo probe. The oligonucle-
otide sequences are as follows: MafA Isl-1 wild type, 7,822-CGTAACGTTA
ATGGAAGATGCTTGCTGCAG-7793, and MafA Isl-1 mutant, 5
-GCCGTAAC
GTGCCGGGAAGATGCT-3
, with the mutation underlined. The reactions were
allowed to proceed at 30°C for 20 min in a buffer containing 10 mmol/l HEPES
(pH 7.8), 75 mmol/l KCL, 2.5 mmol/l MgCl2, 0.1 mmol/l EDTA, 1 mmol/l
dithiothreitol, 3% (v/v) Ficoll, 1 mg/ml BSA, and 1 g poly(dI-dC). Competition
experiments were performed using 100-fold molar excess of unlabeled wild-
type or mutant oligos. Antibody supershift analyses were performed using a
cocktail of four Isl-1–speciﬁc antibodies (Developmental Studies Hybridoma
Bank, 39.3F7, 39.4D5, 40.2D6, and 40.3A4) preincubated with the Isl-1 protein
or nuclear extract at room temperature for 20 min before adding the DNA
probes. Reactions were separated on 6% nondenaturing polyacrylamide gels at
150V for2hi n0 . 5  tris-borate-EDTA buffer. Gels were dried and visualized
by autoradiography.
Transient transfections: reporter assays. Cultured TC3 cells were trans-
fected using Lipofectamine reagent (Invitrogen) with 1 go fMafA region3:
pTK (wild type and Isl-1 mutant) or the pTK(An) chloramphenicol
acetyltransferase (CAT) vector and 1 g of Rous sarcoma virus enhancer–
driven luciferase (pRSV-Luc). Transfection reporter constructs for MafA were
as described (31). Site-directed mutagenesis (Quickchange Mutagenesis kit,
Stratagene) was used to create a noncomplementary transversional mutation
in the Isl-1 binding site 5
-CACGGCCGTAACGTGCCGGGAAGATGCT
TGCTGC-3
 (mutation is underlined). Cell lysates were prepared 48 h after
transfection, and luciferase (LUC) (Promega) and CAT (32) assays were
performed. CAT values were normalized to the LUC internal control. Each
experiment was performed in triplicate with at least two independently
isolated plasmid preparations.
Chromatin immunoprecipitation. TC3 cells were cultured for 72 h at 4 
10
6 cells per 10-cm dish, then isolated and cross-linked with 1% formaldehyde
in DMEM for 5 min at room temperature. Protein DNA chromatin fragments
were prepared by sonication and precleared with protein A-agarose/salmon
sperm DNA (Millipore, Temecula, CA) for2ha t4°C. The precleared
chromatin was then incubated overnight at 4°C with a cocktail of Isl-1
monoclonal antibodies (Developmental Studies Hybridoma Bank 39.4D5,
39.3F7, 40.3A4, 40.2D6) or as controls, normal mouse immunoglobulin (Santa
Cruz Biotechnology), or no antibody. Antibody-bound chromatin complexes
were precipitated with protein A-agarose beads at 4°C for 4 h. Washed
complexes were eluted from the beads and cross-links reversed. Quantitative
real-time PCR was performed on 	1:20 of the Isl-1–immunoprecipitated DNA
using SYBR Green PCR mater mix (Applied Biosciences) and an ABI Prism
7900 instrument. Input DNA dilutions were used to generate a standard curve
and to normalize ampliﬁcation of the gene of interest (Ct). The enrichment
of target control sequences in the chromatin immunoprecipitation (ChIP)
DNAs (n  3–4) was then calculated relative to the inactive phosphoenol-
pyruvate carboxykinase (PEPCK) promoter set as onefold (Ct). Nonquan-
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immunoprecipitated DNA with Taq polymerase hotstart master mix (5 Prime,
Gaithersburg, MD) and 15 pmol of primer. ChIP PCR amplicons were
visualized using a 1.5% agarose gel stained with ethidium bromide in 1
tris-acetate-EDTA buffer. Each ChIP experiment was repeated at least three
times using independent chromatin preparations. The sequences of the real-
time and standard PCR primers are available upon request.
RESULTS
Isl-1 is efﬁciently and speciﬁcally deleted in the
pancreatic epithelium by E13.5. To inactivate Isl-1
speciﬁcally in the developing pancreatic epithelium, mice
carrying the ﬂoxed allele of Isl-1 (29) were mated to
Pdx-1–driven Cre transgenic mice (28). We anticipated
that Isl-1 inactivation would occur in the pancreatic epi-
thelium around E12.5 based on the detection of Pdx1-Cre
activity in Rosa26R mice (33). However, efﬁcient loss of
Isl-1 protein in Pdx1
 pancreatic progenitors was not
observed until E13.5 (Fig. 1A and B; data not shown), with
the delay likely reﬂecting the accessibility of the Isl-1
locus to Cre and/or Cre expression levels in our strain
background. By E13.5, greater than 90% of epithelial cells
lacked Isl-1, as the percentage of Pdx1
Isl-1
 double-
positive cells was reduced from 1.3% in control pancreata
to 0.1% in the Pdx1-Cre;Isl-1
L/L pancreata (Fig. 1C). The
few remaining Isl-1
 cells in the Pdx1-Cre;Isl-1
L/L pan-
creas were either unrecombined Pdx1
 epithelial cells,
ﬁrst-wave endocrine cells, or mesenchymal cells (24) (data
not shown).
Pdx1-Cre;Isl-1
L/L mice exhibit severe hyperglycemia
and impaired glucose tolerance. Pdx1-Cre;Isl-1
L/L mice
were born at the expected Mendelian ratio and did not
differ from their littermate controls in size at birth (data
not shown). There was also no change in total pancreas
weight up to 3 weeks of age (Fig. 2A). However, both male
and female mutant mice displayed elevated random-fed
glucose levels as early as postnatal day (P)0 that worsened
with age (Fig. 2B and C). Eventually, mutant mice died
between 3 to 8 weeks after birth.
We next evaluated endogenous islet -cell function by
intraperitoneal glucose tolerance tests (IPGTT) in 3-week-
old male and female Pdx1-Cre;Isl-1
L/L and control ani-
mals. Mutant mice had slightly increased blood glucose
levels after an overnight fast that became dramatically
elevated without returning to baseline after administration
of exogenous glucose (Fig. 2D). Although both male and
female mutant mice showed similar -cell dysfunction,
male mutant animals also exhibited growth retardation
shortly after week 3, whereas females remained indistin-
guishable from controls (data not shown).
Pax6
 cell number is decreased postnatally in Pdx1-
Cre;Isl-1
L/L mice because of reduced proliferation
and increased apoptosis. To investigate if the change in
-cell function reﬂected alterations in islet cell number
and/or size, we compared hematoxylin-eosin–stained pan-
creatic sections from control and Pdx1-Cre;Isl-1
L/L ani-
mals. Fewer and smaller islets were found in P4 mutant
mice (Fig. 2E and F), with an even more dramatic differ-
ence by P14 (Fig. 2G and H). The number of late endocrine
progenitors marked by Pax6 expression (30) was quanti-
ﬁed at E15.5, E18.5, and P4 to determine the period of
endocrine cell loss. A 27.2% reduction was observed by
E18.5 (Fig. 3B), with a 39.7% decrease in Pax6
 cells by P4
(Fig. 3A–C). These data show that Isl-1 is involved in
maintaining the Pax6
 endocrine progenitor population,
with their loss in Pdx1-Cre;Isl-1
L/L animals resulting from
either a defect in cell differentiation, proliferation, and/or
survival.
To determine if endocrine cell proliferation and/or sur-
vival was affected in the mutant pancreata, we next
performed BrdU incorporation and TUNEL to evaluate
Control
Pdx1-Cre;Isl-1L/L
E13.5
A
B
E13.5
%
 
o
f
 
I
s
l
-
1
 
e
x
p
r
e
s
s
i
n
g
 
 
c
e
l
l
s
*
C
Isl-1/Pdx1
Control
Pdx1-Cre;Isl-1L/L
0.4
0.8
1.2
0
1.4
0.2
0.6
1.0
*
*
E13.5
FIG. 1. Isl-1 is efﬁciently deleted from the pancreatic epithelium in
Pdx1-Cre;Isl-1
L/L mice at E13.5. A: Immunoﬂuorescence staining of
control E13.5 pancreata shows Isl-1 (red) and Pdx1 (green) costaining
in pancreatic epithelium. B: In Pdx1-Cre;Isl-1
L/L pancreata, virtually no
Pdx1
 cells (green) express Isl-1. The asterisk in A and B denotes
Isl-1
 cells in the mesenchyme or ﬁrst-wave endocrine cells that lack
Pdx1 expression. The inset illustrates a higher magniﬁcation of Isl-1
/
Pdx1
 (yellow) coexpressing cells and individual Pdx1
 or Isl-1
 cells.
C: Quantitative analysis shows a 10-fold reduction in the proportion of
Isl-1
 endocrine cells in the mutant pancreas () compared with
controls (f). To normalize Isl-1
 cell numbers between the control and
mutant, 1,000 Pdx1
 cells were counted for each pancreas, n  3 for
both groups. Data are represented as means  SEM. *P < 0.05. (A
high-quality digital representation of this ﬁgure is available in the
online issue.)
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DIABETES, VOL. 58, SEPTEMBER 2009 2061these processes. A decrease in the rate of endocrine cell
proliferation was ﬁrst observed after birth in the pancreata
of Pdx1-Cre;Isl-1
L/L mice, with a 33.2% reduction in BrdU
incorporating cells at P6 (Fig. 3E–J). Similarly, although
there was not a signiﬁcant change in the number of
apoptotic TUNEL
 cells at E18.5, a twofold increase was
found in P4 mutants (Fig. 3K–P). We next examined by
real-time PCR if mRNA levels of the prosurvival and/or
proapoptosis mediators Bid, Bad, Bax, and Bcl2 was
changed by P7 (34). Only Bad was modestly but signiﬁ-
cantly increased (Fig. 3D). Collectively, these results sug-
gest that a major function of Isl-1 in postnatal animals is to
control the proliferation and survival of endocrine cells.
Isl-1 broadly affects endocrine hormone production.
To investigate if Isl-1 is involved in endocrine hormone
production, we measured the total glucagon and insulin
content of control and mutant pancreata at birth. Interest-
ingly, glucagon and insulin content were reduced in the
Pdx1-Cre;Isl-1
L/L pancreas by 78 and 69%, respectively
(Fig. 4A). These results suggest that the reduction in total
hormone content cannot be solely caused by the loss of
endocrine cell mass described above (Fig. 3A–C). Rather,
Isl-1 is likely to have an additional role in regulating
endocrine hormone production itself. To identify the
cause of this defect in mutant animals, we measured the
cross-sectional area of pancreatic tissue stained for insulin
as an indicator for mature -cell mass at E18.5, P4, and P14
and found signiﬁcant reductions in this population of cells
in mutant animals at all stages examined (Fig. 4B).
To distinguish between changes in endocrine cell num-
ber (both mature and immature) and defects in the differ-
entiation of islet cell subtypes, we immunostained
pancreatic tissues with Pax6 (30) in conjunction with
hormone cocktails (glucagon, insulin, somatostatin, and
ghrelin) at E15.5, E18.5, and P4. Unlike control pancreata,
in which the majority of the Pax6
 endocrine cells also
coexpressed hormones, most of the Pax6
 endocrine cells
in mutant pancreata lacked hormone expression at all
stages examined (Fig. 4C–H). These data suggest that Isl-1
regulates the maturation of pancreatic endocrine cells.
To determine when the defects in endocrine cell differ-
entiation were ﬁrst detectable, we performed immunoﬂu-
orescence analysis at several embryonic stages (E13.5,
E15.5, and E18.5). E13.5 was the earliest time point at
which a reduction in glucagon- and insulin-expressing
cells was evident (Fig. 5A and B) coinciding with the onset
of Isl-1 deletion in our model (Fig. 1). The number of
glucagon
, insulin
, and somatostatin
 cells at E15.5 was
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2062 DIABETES, VOL. 58, SEPTEMBER 2009reduced in mutant mice by 83, 63, and 99%, respectively
(Fig. 5C–F and M). A similar pattern was obtained upon
analysis of hormone mRNA expression by real-time PCR
(Fig. 5N). Notably, the few hormone-expressing cells re-
maining in the mutant pancreas were not Isl-1
 (data not
shown). The number of pancreatic polypeptide
 cells was
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DIABETES, VOL. 58, SEPTEMBER 2009 2063decreased in E18.5 mutant pancreata (Fig. 5O), whereas
islet ghrelin
 (ε )- and exocrine amylase
-expressing cell
numbers were unchanged (Fig. 5K, L, and O and data not
shown). These data strongly suggest that Isl-1 is required
to regulate the formation of respective hormone-produc-
ing cell types.
MafA expression is reduced in the E15.5 Pdx1-Cre;
Isl-1
L/L pancreata. Many islet-enriched transcription fac-
tors are essential regulators of pancreatic development
and/or hormone gene expression (35). Next, we examined
if Isl-1 controls expression of these key regulators. A
dramatic reduction in MafA mRNA levels was observed in
the E15.5 Pdx1-Cre;Isl-1
L/L pancreata, while the expres-
sion of other transcription factors including Ngn3 was
unaffected (Fig. 6A). Quantitative analysis of Ngn3
 cells
from control and mutant pancreata further conﬁrmed
Pdx1-Cre;Isl-1
L/L animals have normal numbers of early
endocrine progenitors (Fig. 6B–D). In addition, decreased
MafA expression in -cells was evident by immunostaining
(Fig. 6E and F). Notably, the known regulators of MafA
transcription (MafB, Pax6, Pdx1, Foxa2, and Nkx2.2)
(19,31) were unaffected in the mutant animals (Fig. 6A, G,
and H and data not shown). In summary, these results
suggest that Isl-1 acts upstream of MafA in -cells.
Isl-1 binds to and activates MafA transcription
through an evolutionarily conserved enhancer. MafA
was originally identiﬁed in the -cell as a transactivator of
the C1 element in the insulin enhancer (36). Because
mRNA and protein levels of previously known MafA
regulators were not affected in Pdx1-Cre;Isl-1
L/L mice
(Fig. 6A and data not shown), we hypothesized that Isl-1
directly controls MafA transcription. The MafA 5
 pro-
moter has six evolutionarily conserved regions, of which
“region 3” is not only the longest and most well conserved
(Fig. 7A) but uniquely capable of driving -cell line–
speciﬁc expression in vitro (31).
ChIP analysis was performed in mouse TC3 cells to
determine if Isl-1 occupied region 3 of the MafA gene. A
signiﬁcant and quantitative enrichment of region 3 was
found compared with PEPCK control sequences by stan-
dard or real-time PCR only after –Isl-1 immunoprecipita-
tion (Fig. 7B and C). Conversely, insulin enhancer
sequences were not enriched in Isl-1 ChIP DNA (Fig. 7C).
Next, we performed electrophoretic mobility shift as-
says with either in vitro translated Myc-tagged Isl-1 or
Ins-1 -cell line nuclear extract to analyze binding to the
Isl-1-like site in a MafA region 3 base pair 7,816 to 7,808
spanning probe (Fig. 7A). Isl-1 indeed bound to this site
C
D
E
F
G
H
E15.5 E18.5                                                          P4
Pax6/Ghr/Som/Glu/Ins
C
o
n
t
r
o
l
P
d
x
1
-
C
r
e
;
I
s
l
-
1
L
/
L
E15.5 E18.5 P4
0
2
4
6
*
0
10
20
30
*
P0
A
I
n
s
u
l
i
n
 
c
o
n
t
e
n
t
 
(
m
g
/
g
)
G
l
u
c
a
g
o
n
 
c
o
n
t
e
n
t
 
(
m
g
/
g
)
* * *
β
-
c
e
l
l
 
M
a
s
s
 
(
m
g
)
0.2
0.4
0
0.6
E18.5 P4 P14
B
P0
FIG. 4. Loss of Isl-1 in the pancreatic epithelium leads to reduced endocrine hormone production. A: Total pancreatic glucagon and insulin content
was reduced in P0 mutant animals by 78 and 69%, respectively. B: Morphometric analysis of insulin
 -cell mass in E18.5, P4, and P14 pancreata,
n  4 for all groups. A and B:* P value <0.05, controls (f) and mutants (). C–H: Immunostaining with an antibody cocktail of -Pax6 (red),
-ghrelin (green), -somatostatin (green), -insulin (blue), and -glucagon (blue) indicates that hormone expression is reduced by E15.5 in
Pax6
 endocrine cells (C and D). Loss of hormone genes continues and the decline in the islet mass begins at E18.5 (E and F) and continues into
postnatal stages P4 (G and H). (A high-quality digital representation of this ﬁgure is available in the online issue.)
ISL-1 AND ENDOCRINE PANCREAS
2064 DIABETES, VOL. 58, SEPTEMBER 2009because the level of the protein DNA complex was re-
duced by addition of excess wild-type and not mutant
competitors (Fig. 7D). Additionally, antibodies against
Isl-1 blocked binding to the MafA probe (Fig. 7D). Muta-
tion of the Isl-1 binding site in region 3 also reduced
reporter activity in TC-3 cells (Fig. 7E). Collectively,
these in vitro and endogenous binding data strongly sug-
gest that Isl-1 is a direct regulator of MafA transcription in
-cells.
DISCUSSION
Ahlgren et al. (24) had shown previously through tissue
recombination studies using Isl-1 null embryos that Isl-1
expression in the mesenchyme is essential for proper
differentiation of the exocrine pancreas, while the epithe-
lial expression of Isl-1 is required for early endocrine
pancreas development). We have identiﬁed novel roles for
Isl-1 later in the pancreatic epithelium. Our ﬁndings estab-
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DIABETES, VOL. 58, SEPTEMBER 2009 2065lish Isl-1 as transcriptional regulator required in the for-
mation, proliferation, and survival of islet -, -, -, and PP
cells after the secondary transition and in postnatal lives.
A striking phenotype of Pdx1-Cre;Isl-1
L/L animals is the
dramatic loss of glucagon, insulin, somatostatin, and pan-
creatic polypeptide expression in developing cells, with a
severe reduction in islet cell mass after birth. Lack of Isl-1
in the developing endocrine pancreas has a global impact
on islet cells, with the exception of ghrelin expression. We
showed that the decrease in , , , and PP production was
not simply the result of a reduction in the Ngn3
 endo-
crine progenitor population but was because of the incom-
plete endocrine cell maturation. Although it is not clear
from this study why ghrelin expression was not affected in
the Pdx1-Cre;Isl-1
L/L animals, it is possible that ε -cells
represent an immature endocrine population that does not
require Isl-1 action. This notion is supported by the fact
that ghrelin-expressing cells are present only during fetal
development and in young animals but not in the mature
pancreas (1).
Although Isl-1 was identiﬁed more than a decade ago, its
direct downstream targets in the islet remain largely
uncharacterized. We identiﬁed MafA as a novel transcrip-
tional target of Isl-1. Notably, MafA mRNA expression was
compromised very early and highly selectively upon Isl-1
inactivation in vivo. Furthermore, Isl-1 binding was de-
tected within the principal MafA transcriptional control
region in vitro and by ChIP in -cell lines. Finally, the
luciferase construct containing mutations in the Isl-1 re-
sponse element exhibited lower activity than the wild-type
region 3 reporter. However, Isl-1 was unable to indepen-
dently activate transfected MafA promoter-driven report-
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2066 DIABETES, VOL. 58, SEPTEMBER 2009ers in non–-cells, as, for example, the relative activity
level of Isl-1 to the vector control with the MafA region 3
reporter equaled 0.76 (0.10)-fold. Similarly, Pdx-1, E47,
and NeuroD1/BETA2, widely accepted insulin gene activa-
tors, are also unable to activate insulin-driven reporters in
non–-cell lines on their own (37–39). Moreover, Isl-1 is
incapable of stimulating a variety of different promoter-
driven reporters under circumstances wherein other LIM-
homeodomain proteins could potentiate (i.e., with E47)
(37). The coactivators that are necessary for mediating
Isl-1 activation in -cells or for region 3 speciﬁcally have
not yet been identiﬁed. The loss of only MafA in -cells
cannot explain the pancreatic phenotype observed in our
Pdx1-Cre;Isl-1
L/L animals. For example, although insulin
A
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/ mice, their total
insulin content remains normal. Again, unlike Pdx1-Cre;
Isl-1
L/L mice, the MafA mutant has no developmental
phenotype but displays compromised -cell activity soon
after birth because of defects in insulin secretion (40).
Isl-1 has been shown to regulate preproglucagon gene
expression in vitro (41) and presumably directly inﬂuences
preproglucagon mRNA levels in Pdx1-Cre;Isl-1
L/L mice. A
small but signiﬁcant decrease in the mRNA level of the
-cell–enriched Arx transcription factor was also ob-
served in mutant animals. Although much is known about
how Arx regulates -cell speciﬁcation (35,42,43), little is
known about its signiﬁcance to -cell maturation and
function. It is also remains to be determined how Isl-1
controls somatostatin and pancreatic polypeptide gene
expression in islet - and PP cell, respectively.
Unlike ﬁrst wave Isl-1
 cells that are postmitotic (24),
subsets of Isl-1
 cells after the secondary transition have
the ability to proliferate (data not shown). Although it is
unknown whether proliferation and/or survival of early
endocrine cells was affected in the Isl-1 null pancreata
(24), our data demonstrated a crucial role of Isl-1 in
regulating endocrine cell growth and survival in young
animals. Growth and maintenance of -cell mass is crucial
to prevent or delay loss of -cells in diabetic patients. We
propose that there are at least three transcriptional mech-
anisms utilized by Isl-1 in islet -cell development and
function: 1) direct regulation of targets bound by Isl-1
alone; 2) targets bound by both Isl-1 and MafA (or other
factors); and perhaps to a lesser extent 3) indirect regu-
lation of targets, bound for example by MafA alone. The
former two are likely involved in regulating genes involved
in cell proliferation and survival, processes unaffected in
MafA null mice. In this regard, Bad gene expression was
downregulated in Pdx1-Cre;Isl-1
L/L mice. However, it is
unclear if this is a direct or indirect response since we
were unable to detect binding of Isl-1 to the proximal Bad
promoter in ChIP assays. Combined genome-wide tran-
scription factor binding and expression proﬁling studies
will need to be performed on factors like Isl-1 to determine
how islet cell differentiation is regulated in mammalian
cells.
Severe hyperglycemia observed in the mutant animals is
likely because of both the loss of islet mass and decreased
hormone expression by the remaining islet cells. The
decrease in islet cell number results from decreased cell
proliferation and increased cell death, changes that be-
came signiﬁcant soon after birth. Isl-1 has important
functions in the differentiation of hormone-producing cells
beyond what was shown previously, but the exact mech-
anism of how Isl-1 regulates its target genes is largely
unknown. In addition, future studies in which Isl-1 is
deleted conditionally in mature -cells will determine if
this factor controls -cell function as well as -cell sur-
vival and proliferation in adult animals.
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